Journal of the Neurological Sciences
Volume 292, Issue 1 , Pages 63-71 , 15 May 2010

Nerve excitability changes after intravenous immunoglobulin infusions in multifocal motor neuropathy and chronic inflammatory demyelinating neuropathy

  • Delphine Boërio

      Affiliations

    • Service de Physiologie, Explorations Fonctionnelles, Hôpital Henri Mondor, Assistance Publique, Hôpitaux de Paris, Créteil, France
    • EA 4391, Excitabilité Nerveuse et Thérapeutique, Université Paris 12, Créteil, France
    • Institut de Myologie, Hôpital Pitié-Salpêtrière, Paris, France
    • ,
  • Alain Créange

      Affiliations

    • EA 4391, Excitabilité Nerveuse et Thérapeutique, Université Paris 12, Créteil, France
    • Service de Neurologie, Hôpital Henri Mondor, Assistance Publique, Hôpitaux de Paris, Créteil, France
    • ,
  • Jean-Yves Hogrel

      Affiliations

    • Institut de Myologie, Hôpital Pitié-Salpêtrière, Paris, France
    • ,
  • Antoine Guéguen

      Affiliations

    • EA 4391, Excitabilité Nerveuse et Thérapeutique, Université Paris 12, Créteil, France
    • Service de Neurologie, Hôpital Henri Mondor, Assistance Publique, Hôpitaux de Paris, Créteil, France
    • ,
  • Dominique Bertrand

      Affiliations

    • Unité de Sensométrie et de Chimiométrie, ENITIAA-INRA, Nantes, France
    • ,
  • Jean-Pascal Lefaucheur

      Affiliations

    • Service de Physiologie, Explorations Fonctionnelles, Hôpital Henri Mondor, Assistance Publique, Hôpitaux de Paris, Créteil, France
    • EA 4391, Excitabilité Nerveuse et Thérapeutique, Université Paris 12, Créteil, France
    • Corresponding Author InformationCorresponding author. Service Physiologie, Explorations Fonctionnelles, Hôpital Henri Mondor, 51 avenue de Lattre de Tassigny, 94010 Créteil cedex, France. Tel.: +33 1 4981 2694; fax: +33 1 4981 4660.

Received 18 July 2009 ,Revised 22 December 2009 ,Accepted 2 February 2010.

References 

  1. Hughes RA, Bouche P, Cornblath DR, Evers E, Hadden RD, Hahn A, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol. 2006;13:326–332
  2. van Schaik IN, Bouche P, Illa I, Léger JM, Van den Bergh P, Cornblath DR, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Eur J Neurol. 2006;13:802–808
  3. Hahn AF, Bolton CF, Zochodne D, Feasby TE. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study. Brain. 1996;119:1067–1077
  4. Mendell JR, Barohn RJ, Freimer ML, Kissel JT, King W, Nagaraja HN, et al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology. 2001;56:445–449
  5. Vermeulen M, van Doorn PA, Brand A, Strengers PF, Jennekens FG, Busch HF. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry. 1993;56:36–39
  6. Chaudhry V, Corse AM, Cornblath DR, Kuncl RW, Drachman DB, Freimer ML, et al. Multifocal motor neuropathy: response to human immune globulin. Ann Neurol. 1993;33:237–242
  7. Kaji R, Shibasaki H, Kimura J. Multifocal demyelinating motor neuropathy: cranial nerve involvement and immunoglobulin therapy. Neurology. 1992;42:506–509
  8. Nobile-Orazio E, Meucci N, Barbieri S, Carpo M, Scarlato G. High-dose intravenous immunoglobulin therapy in multifocal motor neuropathy. Neurology. 1993;43:537–544
  9. Léger JM, Chassande B, Musset L, Meininger V, Bouche P, Baumann N. Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain. 2001;124:145–153
  10. Van den Berg LH, Kerkhoff H, Oey PL, Franssen H, Mollee I, Vermeulen M, et al. Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry. 1995;59:248–252
  11. Van den Berg LH, Franssen H, Wokke JH. The long-term effect of intravenous immunoglobulin treatment in multifocal motor neuropathy. Brain. 1998;121:421–428
  12. Créange A, Gregson NA, Hughes RA. Intravenous immunoglobulin modulates lymphocyte CD54 and monocyte FcgammaRII expression in patients with chronic inflammatory neuropathies. J Neuroimmunol. 2003;135:91–95
  13. Dalakas M. Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. Neurology. 2002;59:13–21
  14. Kazatchkine M, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med. 2001;345:747–755
  15. Bostock H, Cikurel K, Burke D. Threshold tracking techniques in the study of human peripheral nerve. Muscle Nerve. 1998;21:137–158
  16. Kiernan MC, Burke D, Andersen KV, Bostock H. Multiple measures of axonal excitability: a new approach in clinical testing. Muscle Nerve. 2000;23:399–409
  17. Krishnan AV, Lin CS, Park SB, Kiernan MC. Assessment of nerve excitability in toxic and metabolic neuropathies. J Peripher Nerv Syst. 2008;13:7–26
  18. Lefaucheur JP, Boërio D, Hogrel JY, Créange A. Etude de l'excitabilité nerveuse dans l'exploration des neuropathies dysimmunitaires. Rev Neurol (Paris). 2006;162:3S19-28
  19. Kiernan MC, Guglielmi JM, Kaji R, Murray NM, Bostock H. Evidence for axonal membrane hyperpolarization in multifocal motor neuropathy with conduction block. Brain. 2002;125:664–675
  20. Priori A, Cinnante C, Pesenti A, Carpo M, Cappellari A, Nobile-Orazio E, et al. Distinctive abnormalities of motor axonal strength–duration properties in multifocal motor neuropathy and in motor neurone disease. Brain. 2002;125:2481–2490
  21. Kleyweg RP, van der Meché FGA, Schmitz PIM. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain–Barre syndrome. Muscle Nerve. 1991;14:1103–1109
  22. Ingram DA, Davis GR, Swash M. The double collision technique: a new method for measurement of the motor nerve refractory period distribution in man. Electroencephalogr Clin Neurophysiol. 1987;66:225–234
  23. Boërio D, Hogrel JY, Créange A, Lefaucheur JP. A reappraisal of various methods for measuring motor nerve refractory period in humans. Clin Neurophysiol. 2005;116:969–976
  24. Kiernan MC, Mogyoros I, Burke D. Differences in the recovery of excitability in sensory and motor axons of human median nerve. Brain. 1996;119:1099–1105
  25. Brismar T. Changes in electrical threshold in human peripheral neuropathy. J Neurol Sci. 1985;68:215–223
  26. Bostock H, Bergmans J. Post-tetanic excitability changes and ectopic discharges in a human motor axon. Brain. 1994;117:913–928
  27. Cappelen-Smith C, Kuwabara S, Lin CS, Mogyoros I, Burke D. Activity-dependent hyperpolarization and conduction block in chronic inflammatory demyelinating polyneuropathy. Ann Neurol. 2000;48:826–832
  28. Cappelen-Smith C, Kuwabara S, Lin CS, Burke D. Abnormalities of axonal excitability are not generalized in early multifocal motor neuropathy. Muscle Nerve. 2002;26:769–776
  29. Cappelen-Smith C, Kuwabara S, Lin CS, Mogyoros I, Burke D. Membrane properties in chronic inflammatory demyelinating polyneuropathy. Brain. 2001;124:2439–2447
  30. Cappelen-Smith C, Lin CS, Kuwabara S, Burke D. Conduction block during and after ischaemia in chronic inflammatory demyelinating polyneuropathy. Brain. 2002;125:1850–1858
  31. Bostock H, Rothwell JC. Latent addition in motor and sensory fibres of human peripheral nerve. J Physiol (London). 1997;498:277–294
  32. Mogyoros I, Kiernan MC, Burke D. Strength–duration properties of human peripheral nerve. Brain. 1996;119:439–447
  33. Craner MJ, Newcombe J, Black JA, Hartle C, Cuzner ML, Waxman SG. Molecular changes in neurons in multiple sclerosis: altered axonal expression of Nav1.2 and Nav1.6 sodium channels and Na+/Ca2+ exchanger. Proc Natl Acad Sci U S A. 2004;101:8168–8173
  34. Bechtold DA, Smith KJ. Sodium-mediated axonal degeneration in inflammatory demyelinating disease. J Neurol Sci. 2005;233:27–35
  35. Stys PK, Waxman SG. Activity-dependent modulation of excitability: implication for axonal physiology and physiolpathology. Muscle Nerve. 1994;17:969–974
  36. Vucic S, Black KR, Chong PS, Cros D. Multifocal motor neuropathy: decrease in conduction blocks and reinnervation with long-term IVIg. Neurology. 2004;63:1264–1269
  37. Vucic S, Black K, Baldassari LE, Tick Chong PS, Dawson KT, Cros D. Long-term effects of intravenous immunoglobulin in CIDP. Clin Neurophysiol. 2007;118:1980–1984
  38. Misawa S, Kuwabara S, Kanai K, Tamura N, Nakata M, Ogawara K, et al. Nodal persistent Na+ currents in human diabetic nerves estimated by the technique of latent addition. Clin Neurophysiol. 2006;117:815–820
  39. Tamura N, Kuwabara S, Misawa S, Kanai K, Nakata M, Sawai S, et al. Increased nodal persistent Na+ currents in human neuropathy and motor neuron disease estimated by latent addition. Clin Neurophysiol. 2006;117:2451–2458
  40. Boërio D, Hogrel JY, Lefaucheur JP, Wang FC, Verschueren A, Pouget J, et al. Stimulus–response curve of human motor nerves: multicenter assessment of various indexes. Neurophysiol Clin. 2008;38:31–38
  41. Mogyoros I, Lin C, Dowla S, Grosskreutz J, Burke D. Reproducibility of indices of axonal excitability in human subjects. Clin Neurophysiol. 2000;111:23–28
  42. Ghosh A, Virgincar A, Kennett R, Busby M, Donaghy M. The effect of treatment upon temporal dispersion in IvIg responsive multifocal motor neuropathy. J Neurol Neurosurg Psychiatry. 2005;76:1269–1272
  43. Van Doorn PA, Vermeulen M, Brand A, Mulder PG, Busch HF. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy. Clinical and laboratory characteristics associated with improvement. Arch Neurol. 1991;48:217–220

PII: S0022-510X(10)00059-6

doi: 10.1016/j.jns.2010.02.002

Journal of the Neurological Sciences
Volume 292, Issue 1 , Pages 63-71 , 15 May 2010

Article Tools

* Image Usage & Resolution